Literature DB >> 20409756

Inflammatory muscle diseases: a critical review on pathogenesis and therapies.

Marinos C Dalakas1.   

Abstract

Based on unique clinicopathological criteria, the most common immune inflammatory muscle disorders include Dermatomyositis (DM), Polymyositis (PM), Necrotizing Myositis (NM), and sporadic Inclusion Body Myositis (sIBM). DM is an undeniably a complement-mediated microangiopathy with destruction of capillaries, hypoperfusion, and inflammatory cell stress on the perifascicular regions. Necrotizing Myopathy is a poorly studied subacute myopathy triggered by toxic, viral, or autoimmune factors with macrophages as the final effector cells. In PM and IBM cytotoxic CD8-positive T-cells clonally expand in situ and invade MHC-I-expressing muscle fibers. In sIBM, in addition to autoimmune inflammation, there are degenerative features characterized by vacuolization and accumulation of stressor and amyloid-related molecules. Advances in the immunobiology of these disorders are discussed including the interaction between pro-inflammatory and beta-amyloid or stressor proteins. A critical review regarding tissue biomarkers and strategies for more effective treatments are presented. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409756     DOI: 10.1016/j.coph.2010.03.001

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  30 in total

1.  Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.

Authors:  Isabela Bruna Pires Borges; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2018-12-05       Impact factor: 2.631

2.  Strength training increases the size of the satellite cell pool in type I and II fibres of chronically painful trapezius muscle in females.

Authors:  Abigail L Mackey; Lars L Andersen; Ulrik Frandsen; Gisela Sjøgaard
Journal:  J Physiol       Date:  2011-09-26       Impact factor: 5.182

3.  Whole-body MRI in adult inflammatory myopathies: Do we need imaging of the trunk?

Authors:  Lukas Filli; Britta Maurer; Andrei Manoliu; Gustav Andreisek; Roman Guggenberger
Journal:  Eur Radiol       Date:  2015-04-24       Impact factor: 5.315

Review 4.  A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.

Authors:  A M Clerici; G Bono; M L Delodovici; G Azan; G Cafasso; G Micieli
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 5.  The role of mitochondria in neurodegenerative diseases.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Valeria Gregorelli; Paola Tonin; Giuliano Tomelleri; Alessandro Padovani
Journal:  J Neurol       Date:  2011-05-22       Impact factor: 4.849

6.  The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.

Authors:  Alicia N Minniti; Macarena S Arrazola; Marcela Bravo-Zehnder; Francisca Ramos; Nibaldo C Inestrosa; Rebeca Aldunate
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

Review 7.  Chronic inflammatory muscle diseases and risk of coronary artery disease.

Authors:  Betul M Gundogdu; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

8.  Nailfold capillaroscopic changes in dermatomyositis and polymyositis.

Authors:  A Manfredi; M Sebastiani; G Cassone; N Pipitone; D Giuggioli; M Colaci; C Salvarani; C Ferri
Journal:  Clin Rheumatol       Date:  2014-10-17       Impact factor: 2.980

9.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 10.  The role of resistin in inflammatory myopathies.

Authors:  Mária Filková; Ladislav Senolt; Jiří Vencovský
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.